Skip to main content

Table 1 Comparison of clinical features between survival group and death group

From: Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients

  Total patients (n = 90) Survival group (n = 68) Death group (n = 22) P value
Demographic features     
Female, n (%) 57 (63.3) 43 (63.2) 14 (63.6) 0.973
Age, years, mean ± SD 51.9 ± 12.1 49.5 ± 11.4 59.2 ± 11.6 0.001*
Disease duration, months, median (IQR) 2.0 (1.0, 3.8) 2.0 (1.0, 4.0) 1.0 (1.0, 2.8) 0.086
Clinical features     
CADM, n (%) 70 (77.8) 51 (75.0) 19 (86.4) 0.380
Raynaud’s phenomenon, n (%) 9 (10.0) 7 (10.3) 2 (9.1) 1.000
Gottron’s papules, n (%) 61 (67.8) 46 (67.6) 15 (68.2) 1.000
Skin ulcer, n (%) 2 (2.2) 1 (1.5) 1 (4.5) 0.431
Laboratory test     
Serum ferritin, ng/ml, median (IQR) 875.0 (538.2, 1794.2) 734.5 (426.2, 1255.5) 2198.5 (1008.8, 2923.5)  < 0.001*
KL-6, U/ml, median (IQR) 939.5 (654.2, 1362.5) 857.0 (640.8, 1202.2) 1736.0 (830.0, 2958.5) 0.002*
CK, U/L, median (IQR) 64.5 (34.2, 122.5) 64.5 (34.0, 114.5) 72.5 (41.8, 132.2) 0.508
CRP, mg/L, median (IQR) 6.4 (2.8, 21.8) 4.4 (1.7, 16.5) 23.0 (11.2, 44.7)  < 0.001*
ESR, mm/h, median (IQR) 32.0 (22.0, 48.0) 30.5 (19.8, 45.0) 37.0 (27.2, 71.8) 0.043*
Lymphocyte, × 109/L, median (IQR) 0.7 (0.6, 1.1) 0.8 (0.6, 1.2) 0.6 (0.4, 0.9) 0.014*
Anti-Ro52, n (%) 64 (71.1) 44 (64.7) 20 (90.9) 0.018*
Anti-MDA5, U/ml, median (IQR) 188.5 (158.5, 206.3) 187.5 (155.5, 206.0) 192.3 (165.8, 205.0) 0.333
ANA ≥ 1:320, n (%) 15 (16.7) 11 (16.2) 4 (18.2) 1.000
HRCT findings     
Total CT GGO score, median (IQR) 2.0 (0.0, 7.8) 0.5 (0.0, 4.0) 11.0 (5.0, 14.8)  < 0.001*
Total CT fibrosis score, median (IQR) 2.0 (1.0, 6.0) 2.0 (0.0, 4.0) 6.0 (2.2, 12.0) 0.001*
Treatment     
Initial combination therapy, n (%) 58 (64.4) 53 (77.9) 5 (22.7)  < 0.001*
IVIG, n (%) 43 (47.8) 31 (45.6) 12 (54.5) 0.465
  1. CADM, clinically amyopathic dermatomyositis; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; CK, creatine kinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; anti-MDA5, anti-melanoma differentiation-associated protein-5; ANA, anti-nuclear antibody; HRCT, high-resolution CT; GGO, ground-glass opacity; CNI, calcineurin inhibitors; CYC, cyclophosphamide; IVIG, intravenous immunoglobulin; SD, standard deviation; IQR, interquartile range
  2. *Significant